Are Chinese Price Cut Fears Overstated? Volume Likely To Drive Pharma Industry Growth, Analysts Say
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - As China gets closer to completing its initial $124 billion healthcare reforms next year, analysts are expecting a strong surge in volume-driven growth backed by more provincial drug reimbursement. A top priority of the Chinese reforms is to extend healthcare insurance to 90 percent (1.3 billion) of China's population by the end of 2011, a goal most expect the government to reach
You may also be interested in...
Anhui Model Suggests More Pricing Pressure From Chinese Drug Tenders
HONG KONG - Meetings with government officials involved with the tender process in China's Anhui province suggest that the impact of price cuts for essential drugs has been greater than expected, Morgan Stanley analysts say in a June 6 research report
Anhui Model Suggests More Pricing Pressure From Chinese Drug Tenders
HONG KONG - Meetings with government officials involved with the tender process in China's Anhui province suggest that the impact of price cuts for essential drugs has been greater than expected, Morgan Stanley analysts say in a June 6 research report
What Does China's Price Manipulation Ruling On Unilever Mean For Global Pharma? (Part 2 of 2)
[Editor's note: This is part two of a two-part feature; part one covered the background of China's National Development and Reform Commission charge against consumer goods company Unilever and what multinational companies operating in China should take away from the incident. This second part looks at the larger impact of China's inflation on pharma companies.]